Astellas Pays $50M for Access to Taysha's Rett, GAN Programs

Dallas-based Taysha Gene Therapies has entered into a strategic equity investment and licensing deal with Astellas. The Tokyo-baesd pharma stands to gain access to Taysha’s gene therapy development programs for Rett syndrome and GAN.